Natural polyphenols and their synthetic analogs as emerging anticancer agents

Current Drug Targets

Volumn 17, Issue 11, 2016, Pages

  Colomer, R ^a   Sarrats, A ^b   Lupu, R ^c   Puig, T ^b  

^a HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^b UNIVERSITY OF GIRONA   (Spain)

^c MAYO CLINIC   (United States)

Author keywords

Clinical trials; EGCG; FASN; Green tea polyphenols; Mouse models; Receptor tyrosine kinases; Signaling pathways; Targets

Indexed keywords

CATECHIN; DRUG ANALOG; EPICATECHIN; EPIGALLOCATECHIN GALLATE; LIGNAN; POLYPHENOL; PROTEASOME; PROTEIN TYROSINE KINASE; STILBENE; TELOMERASE; TRANSCRIPTION FACTOR;

CANCER STEM CELL; CARCINOGENIC ACTIVITY; CHEMICAL STRUCTURE; CHEMOPROPHYLAXIS; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; FATTY ACID METABOLISM; GENETIC TRANSCRIPTION; HUMAN; LIPID RAFT; MALIGNANT NEOPLASM; METHYLATION; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHOSPHORYLATION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TEA;

EID: 84984830530     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/1389450117666160112113930     Document Type: Review

References (134)

1. Kandaswami C, Kanadaswami C, Lee L-T, et al. The antitumor activities of flavonoids. In vivo 2005; 19: 895-909.
2. Mulvihill EE, Huff MW. Antiatherogenic properties of flavonoids: implications for cardiovascular health. Can J Cardiol 2010; 26 Suppl A: 17-21.
3. Ramassamy C. Emerging role of polyphenolic compounds in the treatment of neurodegenerative diseases: a review of their intracellular targets. Eur J Pharmacol 2006; 545: 51-64.
4. Li A-N, Li S, Zhang Y-J, et al. Resources and Biological Activities of Natural Polyphenols. Nutrients 2014; 6: 6020-47.
5. Kondratyuk TP, Pezzuto JM. Natural Product Polyphenols of Relevance to Human Health. Pharm Biol 2004; 42: 46-63.
6. Pandey KB, Rizvi SI. Plant polyphenols as dietary antioxidants in human health and disease. Oxid Med Cell Longev 2009; 2: 270-8.
7. González-Castejón M, Rodriguez-Casado A. Dietary phytochemicals and their potential effects on obesity: A review. Pharmacol Res 2011; 64: 438-55.
8. Bertelli A, Bertelli AA, Gozzini A, Giovannini L. Plasma and tissue resveratrol concentrations and pharmacological activity. Drugs Exp Clin Res 1998; 24: 133-8.
9. Roupe KA, Remsberg CM, Yáñez JA, Davies NM. Pharmacometrics of stilbenes: seguing towards the clinic. Curr Clin Pharmacol 2006; 1: 81-101.
10. Milder IE, Arts IC, van de Putte B, Venema DP, Hollman PC. Lignan contents of Dutch plant foods: a database including lariciresinol, pinoresinol, secoisolariciresinol and matairesinol. Br J Nutr 2005; 93: 393-402.
11. Tsao R. Chemistry and biochemistry of dietary polyphenols. Nutrients 2010; 2: 1231-46.
12. Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem 2011; 82: 1807-21.
13. Manach C, Scalbert A, Morand C, Rémésy C, Jiménez L. Polyphenols: food sources and bioavailability. Am J Clin Nutr 2004; 79: 727-47.
14. D’Archivio M, Filesi C, Di Benedetto R, et al. Polyphenols, dietary sources and bioavailability. Ann Ist Super Sanita 2007; 43: 348-61.
15. Day AJ, Williamson G. Biomarkers for exposure to dietary flavonoids: a review of the current evidence for identification of quercetin glycosides in plasma. Br J Nutr 2001; 86 Suppl 1: 105-10.
16. Hollman PC, Tijburg LB, Yang CS. Bioavailability of flavonoids from tea. Crit Rev Food Sci Nutr 1997; 37: 719-38.
17. Dangles O, Dufour C, Manach C, Morand C, Remesy C. Binding of flavonoids to plasma proteins. Methods Enzymol 2001; 335: 319-33.
18. Wiseman S, Mulder T, Rietveld, A. Tea Flavonoids: Bioavailability in vivo and effects on cell signaling pathways. Antioxid Redox Signal 2001; 3(6): 1009-21.
19. Yang CS, Chen L, Lee MJ, et al. Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol Biomarkers Prev 1998; 7(4): 351-4.
20. Van Amelsvoort JM, Van Hof KH, Mathot JN, et al. Plasma concentrations of individual tea catechins after a single oral dose in humans. Xenobiotica 2001; 31: 891-901.
21. Stalmach A, Troufflard S, Serafini M, Crozier A. Absorption, metabolism and excretion of Choladi green tea flavan-3-ols by humans. Mol Nutr Food Res 2009; 53 Suppl 1: 44-53.
22. Ullmann U, Haller J, Decourt JP, et al. A single ascending dose study of epigallocatechin gallate in healthy volunteers. J Int Med Res 2003; 31: 88-101.
23. Lee M-J, Maliakal P, Chen L, et al. Pharmacokinetics of tea catechins after ingestion of green tea and (-)-epigallocatechin-3-gallate by humans: formation of different metabolites and individual variability. Cancer Epidemiol Biomarkers Prev 2002; 11: 1025-32.
24. Chow HH, Cai Y, Alberts DS, et al. Phase I pharmacokinetic study of tea polyphenols following single-dose administration of epigallocatechin gallate and polyphenon E. Cancer Epidemiol Biomarkers Prev 2001; 10: 53-8.
25. Natsume M, Osakabe N, Oyama M, et al. Structures of (-)-epicatechin glucuronide identified from plasma and urine after oral ingestion of (-)-epicatechin: differences between human and rat. Free Radic Biol Med 2003; 34: 840-9.
26. Del Rio D, Stalmach A, Calani L, Crozier A. Bioavailability of coffee chlorogenic acids and green tea flavan-3-ols. Nutrients 2010; 2: 820-33.
27. Landis-Piwowar K, Chen D, Foldes R, Chan T-H, Dou QP. Novel epigallocatechin gallate analogs as potential anticancer agents: a patent review (2009 - present). Expert Opin Ther Pat 2013; 23: 189-202.
28. Liao S, Kao YH and Hiipakka RA. Green tea: biochemical and biological basis for health benefits. Vitam Horm 2001; 62: 1-94.
29. Fujiki H. Two stages of cancer prevention with green tea. J Cancer Res Clin Oncol 1999; 125: 589-97.
30. Yang G, Zheng W, Xiang YB, et al. Green tea consumption and colorectal cancer risk: a report from the Shanghai Men’s Health Study. Carcinogenesis 2011; 32: 1684-8.
31. Surh YJ. Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer 2003; 3: 768-80.
32. Yang CS, Wang X, Lu G, et al. Cancer prevention by tea: animal studies, molecular mechanisms and human relevance. Nat Rev Cancer 2009; 9: 429-39.
33. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000; 103: 211-225.
34. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: receptor heterodimerization in development and cancer. Embo J 2000; 19: 3159-67.
35. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4: 505-18.
36. Shimizu M, Weinstein IB. Modulation of signal transduction by tea catechins and related phytochemicals. Mutat Res 2005; 591: 147-160.
37. Liang YC, Lin-shiau SY, Chen CF, et al. Suppression of extracellular signals and cell proliferation through EGF receptor binding by (-)-epigallocatechin gallate in human A431 epidermoid carcinoma cells. J Cell. Biochem 1997; 67: 55-65.
38. Masuda M, Suzui M, Weinstein IB. Effects of epigallocatechin -3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2001; 7: 4220-422.
39. Masuda M, Suzui M, Lim JT, et al. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J Exp Ther Oncol 2002; 2: 350-59.
40. Masuda M, Suzui M, Lim JT, Weinstein IB. Epigallocatechin -3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clin Cancer Res 2003; 9: 3486-91.
41. Shimizu M, Deguchi A, Lim JT, et al. (-)-Epigallocatechin gallate and polyphenon E inhibit growth and activation of the epidermal growth factor receptor and human epidermal growth factor receptor -2 signaling pathways in human colon cancer cells. Cli Cancer Res 2005; 11: 2735-46.
42. Chang CM, Chang PY, Tu MG, et al. Epigallocatechin gallate sensitizes CAL-27 human oral squamous cell carcinoma cells to the anti-metastatic effects of gefitinib (Iressa) via synergistic suppression of epidermal growth factor receptor and matrix metalloproteinase -2. Oncol Rep 2012; 28(5): 1799-807.
43. Shimizu M, Deguchi A, Joe AK, et al. EGCG inhibits activation of HER3 and expression of cyclooxygenase-2 in human colon cancer cells. J Exp Ther Oncol. 2005; 5: 69-78.
44. Pianetti S, Guo S, Kavanagh KT, et al. Green tea polyphenol epigallocatechin -3 gallate inhibits Her-2/neu signaling, proliferation, and transformed phenotype of breast cancer cells. Cancer Res 2002; 62: 652-55.
45. Shimizu M, Shirakami Y, Sakai H, et al. EGCG inhibits activation of the insulin-like growth factor (IGF)/IGF-1 receptor axis in human hepatocellular carcinoma cells. Cancer Lett. 2008; 262: 10-18.
46. Adhami VM, Siddiqui IA, Ahmad N, Gupta S, Mukhtar H. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res. 2004; 64: 8715-22.
47. Kang HG, Jenabi JM, Liu XF, et al. Inhibition of the insulin-like growth factor I receptor by epigallocatechin gallate blocks proliferation and induces the death of Ewing tumor cells. Mol Cancer Ther 2010; 9(5): 1396-407.
48. Gray AL, Stephens CA, Bigelow RL, et al. The polyphenols (-)-epigallocatechin-3-gallate and luteolin synergistically inhibit TGF-β-induced myofibroblast phenotypes through RhoA and ERK inhibition. Plos One 2014; 9(10): e109208.
49. Shen X, Zhang Y, Feng T, et al. Epigallocatechin-3-gallate inhibits cell growth, induces apoptosis and causes S phase arrest in hepatocellular carcinoma by suppressing the AKT pathway. Int J Oncol 2014; 44(3): 791-6.
50. Singh M, Singh R, Bhui K, et al. Tea polyphenols induce apoptosis through mitochondrial pathway and by inhibiting nuclear factor -kappaB andAkt activation in human cervical cancer cells. Oncol Res 2011; 19(6): 245-57.
51. Sah JF, Balasubramanian S, Eckert RL, et al. Epigallocatechin -3-gallate inhibits epidermal growth factor receptor signaling pathway. Evidence for direct inhibition of ERK1/2 and AKT kinases. J Biol Chem. 2004; 279: 12755-62.
52. Chung JY, Park JO, Phyu H, et al. Mechanisms of inhibition of the Ras-MAP kinase signaling pathway in 30.7b Ras 12 cells by tea polyphenols (-)-epigallocatechin-3-gallate and theaflavin-3,3’-digallate. Faseb J 2001; 15: 2022-24.
53. Afaq F, Adhami VM, Ahmad N, et al. Inhibition of ultraviolet B-mediated activation of nuclear factor kappaB in normal human epidermal keratinocytes by green tea Constituent (-)-epigallocatechin-3-gallate. Oncogene 2003; 22: 1035-44.
54. Kennedy OD, Kojima A, Hasuma T, et al. Growth inhibitory effect on green tea extract and EGCG in Ehrlich ascites tumor cells involves a cellular thiol-dependent activation of mitogenic-activated protein kinases. Chem Biol Interact 2001; 134: 113-33.
55. Annabi B, Currie JC, Moghrabi A, et al. Inhibition of HuR and MMP-9 expression in macrophage-differentiated HL-60 myeloid leukemia cells by green tea polyphenol EGCG. Leuk Res 2007; 31(9): 1277-84.
56. Vézina A, Chokor R, Annabi B. EGCG targeting efficacy of NF-κB downstream gene products is dictated by the monocytic/ macrophagic differentiation status of promyelocytic leukemia cells. Cancer Immunol Immunother 2012; 61(12): 2321-31.
57. Masuda M, Suzui M, Lim JT, Weinstein IB. Epigallocatechin -3-gallate inhibits activation of HER-2/neu and downstream signaling pathways in human head and neck and breast carcinoma cells. Clin Cancer Res 2003; 9: 3486-91.
58. Chung SS, Vadgama JV. Curcumin and Epigallocatechin Gallate Inhibit the Cancer Stem Cell Phenotype via Down-regulation of STAT3-NFκB Signaling. Anticancer Res 2015; 35(1): 39-46.
59. Luo Y, Liang F, Zhang ZY. PRL1 promotes cell migration and invasion by increasing MMP2 and MMP9 expression through Src and ERK1/2 pathways. Biochemistry 2009; 48: 1838-46.
60. Pines G, Kostler WJ, Yarden Y. Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett 2010; 584: 2699-706.
61. Farabegoli F, Papi A, Orlandi M. (-)-Epigallocatechin-3-gallate downregulates EGFR, MMP-2, MMP-9 EMMPRIN and inhibits the invasion of MCF-7 tamoxifen-resistant cells. Biosci Rep. 2011; 31: 99-108.
62. Wang F, Chang Z, Fan Q, et al. Epigallocatechin-3-gallate inhibits the proliferation and migration of human ovarian carcinoma cells by modulating p38 kinase and matrix metalloproteinase-2. Mol Med Rep 2014; 9(3): 1085-9.
63. Hu G, Han C, Chen J. Inhibition of oncogene expression by green tea and (-)-epigallo-catechin gallate in mice. Nutr Cancer 1995; 24: 203-9.
64. Shim JH, Su ZY, Chae J, et al. Epigallocatechin gallate suppresses lung cancer cell growth through Ras-GTPase-activating protein SH3 domain-binding protein 1. Cancer Prev Res (Phila Pa) 2010; 3: 670-9.
65. Manna S, Mukherjee S, Roy A, et al. Tea polyphenols can restrict benzo[a]pyrene-induced lung carcinogenesis by altered expression of p53-associated genes and H-ras, c-myc and cyclin D1. J Nutr Biochem 2009; 20: 337-49.
66. Smith S. The animal fatty acid synthase: one gene, one polypeptide, seven enzymes. FASEB J 1994; 8(15): 1248-59.
67. Kuhajda FP. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006; 66(12): 5977-80.
68. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007; 7(10): 763-77.
69. Milgraum LZ, Witters LA, Pasternack GR, et al. Enzymes of the fatty acid synthesis pathway are highly expressed in in situ breast carcinoma. Clin Cancer Res 1997; 3(11): 2115-20.
70. Swinnen JV, Roskams T, Joniau S, et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer 2002; 98(1): 19-22.
71. Piyathilake CJ, Frost AR, Manne U, et al. The expression of fatty acid synthase (FASE) is an early event in the development and progression of squamous cell carcinoma of the lung. Hum Pathol 2000; 31(9): 1068-73.
72. Puig T, Turrado C, Benhamú B, et al. Novel Inhibitors of Fatty Acid Synthase with Anticancer Activity. Clin Cancer Res 2009; 15(24): 7608-15.
73. Puig T, Vázquez-Martín A, Relat J, et al. Fatty acid metabolism in breast cancer cells: differential inhibitory effects of epigallocatechin gallate (EGCG) and C75. Breast Canc Res Treat 2008; 109(3): 471-9.
74. Van de Sande T, De Schrijver E, Heyns W, et al. Role of the phosphatidylinositol 3'-kinase/PTEN/Akt kinase pathway in the overexpression of fatty acid synthase in LNCaP prostate cancer cells. Cancer Res 2002; 62(3): 642-6.
75. Menendez JA, Mehmi I, Atlas E, et al. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB. Int J Oncol 2004; 24(3): 591- 608.
76. Yoon S, Lee MY, Park SW, et al. Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells. J Biol Chem 2007; 282(36): 26122-31.
77. Vazquez-Martin A, Colomer R, Brunet J, et al. Overexpression of fatty acid synthase gene activates HER1/HER2 tyrosine kinase receptors in human breast epithelial cells. Cell Prolif 2008; 41(1): 59-85.
78. Relat J, Blancafort A, Oliveras G, et al. Different fatty acid metabolism effects of (-)-epigallocatechin-3-gallate and C75 in adenocarcinoma lung cancer. BMC Cancer 2012; 6: 12-280.
79. Grunt TW, Wagner R, Grusch M, et al. Interaction between fatty acid synthase- and ErbB-systems in ovarian cancer cells. Biochem Biophys Res Commun 2009; 385(3): 454-9.
80. Vergote D, Cren-Olivé C, Chopin V, et al. (-)-Epigallocatechin (EGC) of green tea induces apoptosis of human breast cancer cells but not of their normal counterparts. Breast Canc Res Treat 2002; 76(3): 195-201.
81. Wang X, Tian W. Green tea epigallocatechin gallate: a natural inhibitor of fatty-acid synthase. Biochem Biophys Res Commun 2001; 288(5): 1200-6.
82. Brusselmans K, De Schrijver E, Heyns W, et al. Epigallocatechin -3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells. Int J Cancer 2003; 106(6): 856-62.
83. Pam MH, Lin CC, Kin JK, et al. Tea polyphenol (-)- epigallocatechin 3-gallate suppresses heregulin-beta1-induced fatty acid synthase expression in human breast cancer cells by inhibiting phosphatidylinositol 3-kinase/Akt and mitogen-activated protein kinase cascade signaling. J Agric Food Chem 2007; 55: 5030-37.
84. Puig T, Colomer R, Brunet J, et al. Novel polyhydroxylated compounds as fatty acid synthase (FASN) inhibitors. PCT/EP2008/ 058099, WO2009/000864.
85. Oliveras G, Blancafort A, Urruticoechea A, et al. Novel anti-fatty acid synthase compounds with anti-cancer activity in HER2+ breast cancer. Ann N Y Acad Sci 2010; 1210: 86-92.
86. Turrado C, Puig T, García-Cárceles J, et al. New synthetic inhibitors of fatty acid synthase with anticancer activity. J Med Chem 2012; 55(11): 5013-23.
87. Puig T, Aguilar H, Cufí S, et al. A novel inhibitor of fatty acid synthase shows activity against HER2+ breast cancer xenografts and is active in anti-HER2 drug-resistant cell lines. Breast Cancer Res 2011; 13(6): R131.
88. Tachibana H, Koga K, Fujimura Y, Yamada K. A receptor for green tea polyphenol EGCG. Nat Struct Mol Biol 2004; 11: 380-81.
89. Fujimura Y, Yamada K, Tachibana H. A lipid raft-associated 67kDa laminin receptor mediates suppressive effect of epigallocatechin -3-O-gallate on FcepsilonRI expression. Biochem Biophys Res Commun 2005; 336: 674-85.
90. Tachibana H, Fujimura Y, Yamada K. Tea polyphenol epigallocatechin -3-gallate associates with plasma membrane lipid rafts: lipid rafts mediate anti-allergic action of the catechin. Biofactors 2004; 21: 383-85.
91. Pike LJ, Casey L. Cholesterol levels modulate EGF receptor -mediated signaling by altering receptor function and trafficking. Biochemistry 2002; 41: 10315-22.
92. Sottocornola E, Misasi R, Mattei V, Ciarlo L, Gradini R, Garofalo T, Berra B, Colombo I, Sorice M. Role of gangliosides in the association of ErbB2 with lipid rafts in mammary epithelial HC11 cells. FEBS J 2006; 273: 1821-30.
93. Remacle-Bonnet M, Garrouste F, Baillat G, Andre F, Marvaldi J, Pommier G. Membrane rafts segregate pro- from anti-apoptotic insulin-like growth factor-I receptor signaling in colon carcinoma cells stimulated by members of the tumor necrosis factor superfamily. Am. J Pathol 2005; 167: 761-73.
94. Furuchi T, Anderson RG. Cholesterol depletion of caveolae causes hyperactivation of extracellular signal-related kinase (ERK) J Biol Chem 1998; 273: 21099-104.
95. Adachi S, Nagao T, Ingolfsson HI, et al. The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. Cancer Res 2007; 67: 6493-501.
96. Adachi S, Nagao T, To S, et al. (-)-Epigallocatechin gallate causes internalization of the epidermal growth factor receptor in human colon cancer cells. Carcinogenesis 2008; 29(10): 1986-93.
97. Masuda M, Wakasaki T, Toh S, et al. Chemoprevention of Head and Neck Cancer by Green Tea Extract: EGCG—The Role of EGFR Signaling and “Lipid Raft” J Oncol 2011; 2011: 540148.
98. Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004; 4: 143-53.
99. Singh V, Sharma P, Capalash N. DNA methyltransferase-1 inhibitors as epigenetic therapy for cancer. Curr Cancer Drug Targets 2013; 13(4): 379-99.
100. Jin H, Chen JX, Wang H, et al. NNK-Induced DNA Methyltransferase 1 in Lung Tumorigenesis in A/J Mice and Inhibitory Effects of (-)-Epigallocatechin-3-Gallate. Nutr Cancer 2015; 67(1): 167-76.
101. Fang MZ, Wang Y, Ai N, et al. Tea polyphenol (-)-epigallo- catechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res 2003; 63: 7563-70.
102. Mirza S, Sharma G, Parshad R, et al. Expression of DNA methyltransferases in breast cancer patients and to analyze the effect of natural compounds on DNA methyltransferases and associated proteins. J Breast Cancer 2013; 16(1): 23-31.
103. Qu Y, Dang S, Hou P. Gene methylation in gastric cancer. Clin Chim Acta 2013; 424: 53-65.
104. Yuasa Y, Nagasaki H, Akiyama Y, et al. Relationship between CDX2 gene methylation and dietary factors in gastric cancer patients. Carcinogenesis 2005; 26: 193-200.
105. Hochstrasser M. Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. Curr Opin Cell Biol 1995; 7: 215- 23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7612274
106. Ciechanover A. The ubiquitin-proteasome proteolytic pathway. Cell 1994; 79: 13-21.
107. Hideshima T, Richardson P, Chauhan D et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001; 61: 3071-6.
108. An B, Goldfarb RH, Siman R, Dou QP. Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblasts. Cell Death Differ 1998; 5: 1062-75.
109. Nam S, Smith DM, Dou QP. Ester bond-containing tea polyphenols potently inhibit proteasome activity in vitro and in vivo. J Biol Chem 2001; 276: 13322-30.
110. Naasani I, Seimiya H, Tsuruo T. Telomerase inhibition, telomere shortening, and senescence of cancer cells by tea catechins. Biochem Biophys Res Commun 1998; 249: 391-6.
111. Naasani I, Oh-Hashi F, Oh-Hara T, et al. Blocking telomerase by dietary polyphenols is a major mechanism for limiting the growth of human cancer cells in vitro and in vivo. Cancer Res 2003; 63: 824-30.
112. Dawood S, Austin L, Cristofanilli M. Cancer Stem Cells: Implications for Cancer Therapy. Oncology 2014; 28.
113. Weiswald L-B, Bellet D, Dangles-Marie V. Spherical Cancer Models in Tumor Biology. Neoplasia 2015; 17: 1-15
114. Charafe-Jauffret E, Ginestier C, Iovino F, et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 2010; 16: 45-55.
115. Ginestier C, Hur MH, Charafe-Jauffret E, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007; 1: 555-67
116. Mineva ND, Paulson KE, Naber SP, Yee AS, Sonenshein GE. Epigallocatechin-3-gallate inhibits stem-like inflammatory breast cancer cells. PLoS One 2013; 8: e73464.
117. Lu H, Meng X, Li C, et al. Glucuronides of tea catechins: enzymology of biosynthesis and biological activities. Drug Metab Dispos 2003; 31: 452-61.
118. Kida K, Suzuki M, Matsumoto N, Nanjo F, Hara Y. Identification of biliary metabolites of (-)-epigallocatechin gallate in rats. J Agric Food Chem 2000; 48: 4151-55.
119. Lu H, Meng X, Yang CS. Enzymology of methylation of tea catechins and inhibition of catechol-O-methyltransferase by (-)-epigallocatechin gallate. Drug Metab Dispos 2003; 31: 572-79.
120. Kristin Landis-Piwowar, Di Chen, Robert Foldes, et al. Novel epigallocatechin gallate analogs as potential anticancer agents: a patent review (2009 - present) Expert Opin Ther Pat 2013; 23(2): 10.1517.
121. Lam WH, Kazi A, Kuhn DJ, et al. A potential prodrug for a green tea polyphenol proteasome inhibitor: evaluation of the peracetate ester of (-)-epigallocatechin gallate [(-)-EGCG] Bioorg Med Chem 2004; 12: 5587-93.
122. Kuhn D, Lam WH, Kazi A, et al. Synthetic peracetate tea polyphenols as potent proteasome inhibitors and apoptosis inducers in human cancer cells. Front Biosci 2005; 10: 1010-23.
123. Matsumura K, Kaihatsu K, Mori S, et al. Enhanced anti-tumor activities of (-)-epigallocatechin-3-O-gallate fatty acid monoester derivatives in vitro and in vivo. Biochem Biophys Res Commun 2008; 377: 1118-22.
124. Hakim IA, Harris RB, Brown S, et al. Effect of increased tea consumption on oxidative DNA damage among smokers: a randomized controlled study. J Nutr 2003; 133: 3303S-3309S.
125. Bettuzzi S, Brausi M, Rizzi F, et al. Chemoprevention of human prostate cancer by oral administration of green tea catechins in volunteers with high-grade prostate intraepithelial neoplasia: a preliminary report from a one-year proof-of-principle study. Cancer Res 2006; 66: 1234-40.
126. Tsao AS, Liu D, Martin J, et al. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev 2009; 2: 931-41.
127. Shimizu M, Fukutomi Y, Ninomiya M, et al. Green tea extracts for the prevention of metachronous colorectal adenomas: a pilot study. Cancer Epidemiol Biomarkers Prev 2008; 17: 3020-5.
128. Yang G, Shu X-O, Li H, et al. Prospective cohort study of green tea consumption and colorectal cancer risk in women. Cancer Epidemiol Biomarkers Prev 2007; 16: 1219-23.
129. Zhang M, Holman CDJ, Huang J, Xie X. Green tea and the prevention of breast cancer: a case-control study in Southeast China. Carcinogenesis 2007; 28: 1074-8.
130. Wu AH, Yu MC, Tseng C-C, Hankin J, Pike MC. Green tea and risk of breast cancer in Asian Americans. Int J Cancer 2003; 106: 574-9.
131. Suzuki Y, Tsubono Y, Nakaya N, Koizumi Y, Tsuji I. Green tea and the risk of breast cancer: pooled analysis of two prospective studies in Japan. Br J Cancer 2004; 90: 1361-3.
132. Zhao H, Zhu W, Xie P, et al. A phase I study of concurrent chemotherapy and thoracic radiotherapy with oral epigallocatechin-3-gallate protection in patients with locally advanced stage III non-small-cell lung cancer. Radiother Oncol 2014; 110: 132-6.
133. Zhang G, Wang Y, Zhang Y, et al. Anti-cancer activities of tea epigallocatechin-3-gallate in breast cancer patients under radiotherapy. Curr Mol Med 2012; 12: 163-76.
134. Inoue M, Tajima K, Mizutani M, et al. Regular consumption of green tea and the risk of breast cancer recurrence: follow-up study from the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC), Japan. Cancer Lett 2001; 167: 175-82.